The upper graphs in Panel A show representative flow-cytometric analyses of the percent of circulating anti-CD19 (CD3+ αCD19 chimeric antigen receptor [CAR]+) CAR T cells among total T cells at ...
Refractory multiple myeloma means that your blood cancer isn’t responding to treatment. Your doctor may also refer to this as “progressive disease.” Hearing that your treatment isn’t slowing the ...
In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell lymphoma after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results